NDASUBCUTANEOUSSOLUTION
Approved
Aug 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
SOMATULINE DEPOT (lanreotide acetate) by Ipsen is lanreotide, the active component of somatuline depot is an octapeptide analog of natural somatostatin. Approved for acromegaly, neuroendocrine tumours. First approved in 2007.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOMATULINE DEPOT (lanreotide acetate) is a long-acting somatostatin analog administered as a subcutaneous injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug works by mimicking natural somatostatin, an inhibitory hormone that suppresses tumor growth and hormone secretion. It is indicated for well, moderately differentiated, locally advanced, and metastatic GEP-NETs to improve progression-free survival, positioning it as a key agent in neuroendocrine tumor management.
$0.1BPart D
Mechanism of Action
Lanreotide, the active component of SOMATULINE DEPOT is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.
Indications (2)
Clinical Trials (1)
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Started May 2009
115 enrolled
Carcinoid Syndrome
Worked on SOMATULINE DEPOT at Ipsen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.